Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT07276230
Starting soon Not applicable

Quality of Life Assessment of Caregivers of Patients With Multiple Myeloma

NCT07276230 · tracked via the Priya Life Science France tracker
Sponsor
Assistance Publique - Hôpitaux de Paris
Phase
Not applicable
Started
2026-02-01
Last updated
2025-12-29

Condition(s) studied

Caregivers of Patients With Multiple Myeloma

Investigational drug(s) / intervention(s)

Therapeutic Education and Needs Assessment Program for Caregivers

Therapeutic Education and Needs Assessment Program for Caregivers: Participation in a weekly therapeutic education group for 4 weeks.

Study summary

The diagnosis and treatment of multiple myeloma affect not only the patient but also their family and caregivers. Advances in therapy have transformed the follow-up of patients treated for multiple myeloma. The involvement of informal caregivers has become increasingly essential to ensure adequate home-based care, as most treatments are now delivered on an outpatient basis. Literature reviews suggest that caregivers of cancer patients often face unmet supportive care needs, which in turn negatively impact their quality of life.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: Caregiver : * Designated by a patient followed for multiple myeloma during first-line treatment * Providing weekly assistance to the patient (e.g., shopping, housekeeping, management of daily living activities, healthcare or hygiene support, etc.) * Aged 18 years or older * Fluent in French * Affiliated with or benefiting from a social security system (excluding state medical aid - AME) * Able to provide free, written, and informed consent Exclusion Criteria: Caregiver : * Not designated by the patient as the primary caregiver * Currently being treated for an acute medical condition * Refusal of the caregiver to participate in the study * Under legal protection (guardianship or curatorship)

Primary outcome measure(s)

  • Effectiveness of a needs assessment approach through participation in a therapeutic education program on improving the quality of life of caregivers of patients with multiple myeloma. — 3 months
    Change in caregivers' CarGOQoL (CareGiver Oncology Quality of Life) scores between baseline and 3 months. The higher the score, the better the quality of life.

Trial sites (1)

FacilityCityRegionStatus
Hématologie clinique - Pitié-Salpêtrière Hospital (APHP) Paris France

More Assistance Publique - Hôpitaux de Paris trials in France

Identification of Cutaneous and Blood Biomarkers Predictive of Response to Systemic Treatments During Chronic Inflammatory Skin Diseases Recruiting
VExUS in Ards Patients and Association with AKI Recruiting
Periodontitis and Inflammation: Study on Biological Samples Recruiting
Kinematic Analysis of Latissimus Dorsi Transfer Results for Shoulder External Rotation Resuscitation Starting soon
Creation of a Biological Collection for Medical Research Purposes for Patients at the Reference Center for Rare Diseases of the Blood Vessels of the Brain and Eye at Lariboisière Hospital Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07276230 on ClinicalTrials.gov ↗ ← All trials in France